Sept 30 (Reuters) - Revive Therapeutics Ltd RVV.V :
* Says positive interim results from phase 2a study of revenue-002
(bucillamine) in the treatment of acute gout flares
* CEO says "we are encouraged to see potential efficacy of the higher dose arm
b"
* Says in arm b 67% had a greater than or equal to 50% reduction in target
joint pain score from baseline
* Source text for Eikon ID:nMKWTYlhqa
* Further company coverage RVV.V